Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Glatiramer acetate, interferons (intramuscular, subcutaneous, pegylated) teriflunomide, fumarates (dimethyl, diroximel, monomethyl) fingolimod, siponimod, ozanimod, ponesimod
(D10967)		1件: Glatiramer1件: Glatiramer acetate 💬 20件: MHC1,
MHC1,
MHC1,
MHC1,
MHC1,
MHC1,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2,
MHC2 💬 		32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬1件: 13 💬
2Ozanimod
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 96, 97 💬
3Ozanimod 0.5 MG
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
4Ozanimod 1 MG
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
5Ozanimod cloridrato
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
6Ozanimod HCI
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬
7Ozanimod HCL
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 96, 97 💬
8Ozanimod hydrochloride
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 96, 97 💬
9Ozanimod oral capsule
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬2件: 13, 97 💬
10RPC1063 (equivalent TO ozanimod
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 96 💬
11Select dmts other than ozanimod
(D10967)		1件: Ozanimod2件: Ozanimod hydrochloride (D10967),
Ozanimod 💬 		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬 		4件: Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13 💬